Endpoint
Serum alkaline phosphatase
An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.
CAT:outcome/alkaline-phosphatasereported in U/L5 findings from 2 compounds
What moved it
How to read these marks5 findings · 2 compounds · 4 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| curcumin | no effect | 4 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| sodium benzoate | up | 1 | Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. |
Reported to move it
1 finding
sodium benzoate — increases
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“Administration of SB to rats with hepatocyte injury exacerbated liver damage with a significant increase in the activities of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP).”
Quoted verbatim from Sodium benzoate exacerbates hepatic oxidative stress and inflammation in lipopolysaccharide-induced liver injury in rats.. - Study
- animal · not in humans
- Duration
- 14 days
- Dose
- 600 mg/kg, oral, 14 days
- Population
- rats with LPS-induced (0.25 mg/kg) hepatocyte injury given sodium benzoate 600 mg/kg orally for 14 days; LPS background present in both compared arms
Sodium benzoate exacerbates hepatic oxidative stress and inflammation in lipopolysaccharide-induced liver injury in rats.2023PMID:36927185Permalink
Measured, no effect detected
4 findings
curcumin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×3“There was no significant association between curcumin supplement and ALP [MD (95% CI) of −8.88 (−24.68, 6.93) units/L].”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Dose
- 80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
- Population
- Adults with MAFLD (NAFLD/NASH); 6 RCTs, all using bioavailability-enhanced curcumin forms; liver enzymes were a primary outcome of interest
Effect -8.88 mean difference, 95% CI -24.68 to 6.93
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×3“The mean change in ALP levels was − 0.77 ± 14.54 U/L in the nanocurcumin group and − 5.57 ± 20.37 U/L in the placebo group, with no significant difference between groups in the crude analysis ( P = 0.262).”
Quoted verbatim from Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.. - Study
- RCT
- Dose
- Oral nanomicellar curcumin (nano-curcumin, Exir Nano Sina), one 40 mg capsule twice daily with a main meal (80 mg/day) for 16 weeks
- Population
- Adults aged 30-70 y with NAFLD-associated liver fibrosis of METAVIR stage F2 or higher, Tehran, Iran; 55 randomised and all 55 analysed with no withdrawals (27 nano-curcumin, 28 placebo); secondary endpoint (declared primary outcomes: liver fibrosis and steatosis by FibroScan and the FIB-4 index); unadjusted between-group comparison of change from baseline; the between-group difference remained non-significant after adjustment for baseline values, age, sex, diabetes, calorie intake change and BMI (P = 0.161); serum ALP by enzyme colorimetric method on a Cobas c 311 analyser
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.2025PMID:41168313Industry fundedPermalink
curcumin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×3“Concerning bone formation and mineral metabolism, pooled estimates from seven studies revealed that curcumin did not significantly alter ALP levels (SMD = -1.00, 95% CI = -3.14 to 1.13, p = 0.36).”
Quoted verbatim from Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.. - Study
- animal · not in humans
- Population
- ovariectomized/GIOP/metabolic osteoporosis rodent models, meta-analysis of 7 studies
Effect -1 standardised mean difference, 95% CI -3.14 to 1.13
Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.2026PMID:42656268Permalink
curcumin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×3“Curcumin supplementation significantly reduced ALT (weighted mean difference [WMD], -4.10, 95%CI, -7.16 to -1.04) and AST (WMD, -3.27; 95%CI, -5.16 to -1.39), but not ALP (WMD, -0.49; 95%CI, -1.79 to 0.82).”
Quoted verbatim from Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with nonalcoholic fatty liver disease
Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.2025PMID:38213188Permalink
How it is measured
Serum alkaline phosphatase catalytic activity by clinical para-nitrophenyl-phosphate assay at a stated temperature.
Measured, not recorded
- Subject
- serum alkaline phosphatase
- Measurements
- 1 measurement
- Recorded as a finding
- No
Show what was measured
serum alkaline phosphatase
increases, RR: 6.86, 95% CI: (5.45, 8.27), P < 0.00001
The ALP in the combination group was significantly higher than that in the monotherapy group, and the difference was statistically significant (RR: 6.86, 95% CI: (5.45, 8.27), P < 0.00001).
PMID:35845743 · one of two readings recorded this
Sources cited
5 papers
- Subject
- serum alkaline phosphatase
- Findings
- 5
- Papers
- 5
Integrated meta-analysis and exploratory small-sample machine learning to evaluate curcumin against osteoporosis: a preclinical evidence-based study.record2026PMID:426562681 finding
Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.record2025PMID:382131881 finding
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.record2025PMID:411683131 finding
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.record2023PMID:370378911 finding
Sodium benzoate exacerbates hepatic oxidative stress and inflammation in lipopolysaccharide-induced liver injury in rats.record2023PMID:369271851 finding